Hospira Earnings Fall as Manufacturing Fixes Continue

Hospira continues to shell out money to fix quality issues at its manufacturing plants, costing the company a nearly 73 percent decrease in its earnings per share for the first quarter of 2012. And the company’s Rocky Mount, N.C., manufacturing facility will maintain production and release levels in the 60 to 70 percent range until at least mid-year, Hospira CEO Michael Ball said Tuesday on a conference call with investors. The company has “continued to press forward with implementation of our remediation plan” at the Rocky Mount plant, Ball said. The FDA and Hospira are working on finalizing a date to discuss the plan’s implementation.
Drug Industry Daily